Laxative Use in the Setting of Positive Testing for Clostridium difficile Infection

Infection Control and Hospital Epidemiology

Volumn 38, Issue 12, 2017, Pages 1513-1515

  Ahmad, Syed M ^a   Blanco, Natalia ^b   Dewart, Courtney M ^c   Dobosz, Anna ^a   Malani, Anurag N ^a  

^a Saint Joseph Mercy Health System   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISACODYL; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CORTICOSTEROID; DOCUSATE SODIUM; HISTAMINE H2 RECEPTOR ANTAGONIST; LACTULOSE; LAXATIVE; MACROGOL; MAGNESIUM HYDROXIDE; POLYSTYRENESULFONATE SODIUM; PROTON PUMP INHIBITOR; SENNA EXTRACT;

ADULT; AGED; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE COURSE; DRUG USE; ENZYME IMMUNOASSAY; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL PATIENT; HOSPITAL SERVICE; HUMAN; LABORATORY TEST; LETTER; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; VERY ELDERLY; CLOSTRIDIUM INFECTION; DIFFERENTIAL DIAGNOSIS; DRUG UTILIZATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; DRUG UTILIZATION; FEMALE; HUMANS; LAXATIVES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85038558237     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2017.221     Document Type: Letter

References (10)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate pointprevalence survey of health care-Associated infections. N Engl J Med 2014;370:1198-1208.
2. Lessa FC, Mu Y, BambergWM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-834.
3. Buckel WR, Avdic E, Carroll KC, Gunaseelan V, Hadhazy E, Cosgrove SE. Gut check: Clostridium difficile testing and treatment in the molecular testing era. Infect Control Hosp Epidemiol 2015;36:217-221.
4. Alasmari F, Seiler SM, Hink T, Burnham CA, Dubberke ER. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014;59:216-222.
5. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015;175:1792-1801.
6. Polage CR, Chin DL, Leslie JL, Tang J, Cohen SH, Solnick JV. Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis 2012;74:369-373.
7. Tehrani L, Seville MT. Laxative use and Clostridium difficile testing and treatment. In: Program and abstracts of the Annual Scientific Meeting of the Infectious Diseases Society of America (IDWeek); October 7-11, 2015; San Diego, CA. Abstract no. 956.
8. Rineer S, Dizon J, Logan J, Hsu V. Laxative use and testing delays may overestimate the true burden of Clostridium difficile. In: Program and abstracts of the Annual Scientific Meeting of the Infectious Diseases Society of America (IDWeek); October 7-11, 2015; San Diego, CA. Abstract no. 955.
9. Truong CY, Gombar S, Wilson R, et al. Real-Time electronic tracking of diarrheal episodes and laxatives therapy enables verification of Clostridium difficile clinical testing criteria and reduction of Clostridium difficile infection rates. J Clin Microbiol 2017;55:1276-1284.
10. Polage CR, Solnick JV, Cohen SH. Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clin Infect Dis 2012;55:982-989.